+ Filter



CAR

Anti-CAR Products
- Recombinant Anti-CAR Antibody (MOB-155)
-
- Derivation: Mouse
- Type: IgG
- Application: ELISA, WB, Dot, FuncS
- Recombinant Human Anti-CAR Antibody (MHH-155)
-
- Derivation: Human
- Type: IgG
- Application: WB, ELISA, IHC, FuncS
- Recombinant Anti-CAR Antibody scFv Fragment (MOB-155-S(P))
-
- Derivation: Mouse
- Type: scFv
- Application: WB, Neut, FuncS
- Recombinant Human Anti-CAR Antibody scFv Fragment (MHH-155-S(P))
-
- Derivation: Human
- Type: scFv
- Application: WB, FC, FuncS
- Recombinant Human Anti-CAR Antibody Fab Fragment (MHH-155-F(E))
-
- Derivation: Human
- Type: Fab
- Application: FC, Neut, Funcs
- Recombinant Anti-CAR Antibody Fab Fragment (MOB-155-F(E))
-
- Derivation: Mouse
- Type: Fab
- Application: IF, Neut, FuncS
View More Products
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
Artificial T cell receptors (also known as chimeric T cell receptors, chimeric immunoreceptors, chimeric antigen receptors (CARs)) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell. Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T cell; with transfer of their coding sequence facilitated by retroviral vectors. Artificial T cell receptors are under investigation as a therapy for cancer, using a technique called adoptive cell transfer. T cells are removed from a patient and modified so that they express receptors specific to the particular form of cancer. The T cells, which can then recognize and kill the cancer cells, are reintroduced into the patient. Phase I clinical studies of this approach have shown efficacy.